Response to comments on Zhang et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338-1345
1 Graduate Program in Operations Research, North Carolina State University, Raleigh, NC.
2 Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
3 Department of Public Health Sciences, University of Virginia, Charlottesville, VA.
4 Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
5 Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN Optum Labs, Cambridge, MA.
6 Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI btdenton@umich.edu.